Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Immunogenicity of Ixekizumab (SB35 and Taltz) in Healthy Participants
NCT07789964Phase 1Recruiting
- Sponsor
- Samsung Bioepis
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ixekizumab in psoriasis (2 arms), sponsored by Samsung Bioepis. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Infinity at 85 days, Maximum Observed Plasma Concentration at 85 days and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07789964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789964.